Skip to content
DraconiticResearch
Search Sources API
181,686 studies31 sourcesUpdated 3 min ago
Peer-reviewedCC BY 4.0Cancers

Giant Keratinocyte Carcinomas: Clinical, Histopathological, Molecular and Health-System Factors with Therapeutic Implications—A Structured Narrative Review

  • Andrzej Ciborek1
  • Hanna Krauss2
  • Zuzanna Chęcińska-Maciejewska3
  • Andrzej Kazimierz Jaworek4
4 affiliations
  1. 1Department of Interprofessional Education, Faculty of Medicine and Health Sciences, Calisia University (Uniwersytet Kaliski im. Prezydenta Stanisława Wojciechowskiego), ul. Kaszubska 13, 62-800 Kalisz, Poland
  2. 2Department of Basic Sciences, Calisia University (Uniwersytet Kaliski im. Prezydenta Stanisława Wojciechowskiego), ul. Kaszubska 13, 62-800 Kalisz, Poland
  3. 3Department of Food and Nutrition, Faculty of Medicine and Health Sciences, Calisia University, ul. Kaszubska 13, 62-800 Kalisz, Poland
  4. 4Department of Dermatology, Jagiellonian University Medical College, ul. Mikołaja Kopernika 50, 31-501 Kraków, Poland
Read full textPDFDOICite

Abstract

Background/Objectives: Giant keratinocyte carcinomas, comprising basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) with a maximum diameter ≥ 5 cm, pose substantial clinical challenges. This structured narrative review distinguishes giant-specific findings from contextual evidence in advanced or high-risk disease. Methods: The synthesis uses a retained bibliography assembled from searches described in earlier drafts as covering PubMed/MEDLINE and PubMed Central from January 2015 to March 2026, supplemented by citation and guideline searching and a focused update reported through 4 September 2026. A record-level search and screening log is unavailable; historical selection counts cannot be independently reconstructed. The review protocol was not registered, and exhaustive coverage or full PRISMA compliance is not claimed. Sources were classified by design and directness, with descriptive consideration of methodological limitations. Results: The retained set contains 51 sources: nine containing direct giant-specific clinical evidence and 42 providing contextual evidence. Direct evidence consists principally of case reports, retrospective or comparative studies and a giant-cSCC literature synthesis. It links giant BCC with prolonged lesion duration, ulceration, deeper invasion and reconstructive burden. Giant-cSCC outcomes vary substantially between reported series. Evidence for Hedgehog-pathway inhibition, PD-1 blockade and most molecular mechanisms derives mainly from conventional or advanced disease. Conclusions: Management requires multidisciplinary assessment integrating size, pathological risk, resectability and patient factors. Giant-specific molecular and therapeutic evidence remains limited, and contextual treatment effects should not be interpreted as effects established specifically in tumours ≥ 5 cm.

Related

  1. Clinical and histopathological patterns of American cutaneous leishmaniasis: diagnostic and therapeutic implications for targeted therapy
    Victor Rosette, Kinan Drak Alsibai, Magalie Pierre-Demar +3
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textEpidemiology & public healthCrossref
  2. AI-Guided Histopathological and Molecular Phenotyping of Salivary Glands in Sjögren's Disease: Subtyping, Mechanistic Insights, and Translational Implications-A Systematic Review and Structured Functional Synthesis.
    Carlos M Ardila, Eliana Pineda-Vélez, Anny M Vivares-Builes
    Medical sciences (Basel, Switzerland)Peer-reviewedCC BYFull textPhysiologyEurope PMC
  3. The Therapeutic Effects of 4-Aminopyridine Administration via Phonophoresis on Sutured Postoperative Wounds: A Histopathological, Immunohistochemical, Molecular, and Morphometric Study
    Selma Yaman, Hamit Yilmaz, Gamze Altun +3
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Pheochromocytomas with Aggressive Histopathological Features Have Reduced Apelin and Increased VEGF Expression: Diagnostic and Prognostic Implications.
    Hatice Çalışkan Burgucu, Tuğba Günler, Ethem Ömeroğlu +2
    Pathophysiology : the official journal of the International Society for PathophysiologyPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  5. Extracorporeal kidney support in neonates and infants: therapeutic perspectives and outcomes in multiple organ dysfunction syndrome—a structured narrative review
    Gulmira Zhauarova, Dinagul Baesheva, Gulnur Nadirbekova +3
    Frontiers in pediatricsPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{ciborek2026giant,
  title = {{Giant Keratinocyte Carcinomas: Clinical, Histopathological, Molecular and Health-System Factors with Therapeutic Implications—A Structured Narrative Review}},
  author = {Andrzej Ciborek and Hanna Krauss and Zuzanna Chęcińska-Maciejewska and Andrzej Kazimierz Jaworek},
  journal = {Cancers},
  year = {2026},
  month = oct,
  doi = {10.3390/cancers18203367},
  url = {https://www.mdpi.com/2072-6694/18/20/3367},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Giant Keratinocyte Carcinomas: Clinical, Histopathological, Molecular and Health-System Factors with Therapeutic Implications—A Structured Narrative Review
AU  - Andrzej Ciborek
AU  - Hanna Krauss
AU  - Zuzanna Chęcińska-Maciejewska
AU  - Andrzej Kazimierz Jaworek
PY  - 2026
DA  - 2026/10/01
JO  - Cancers
DO  - 10.3390/cancers18203367
UR  - https://www.mdpi.com/2072-6694/18/20/3367
AB  - Background/Objectives: Giant keratinocyte carcinomas, comprising basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) with a maximum diameter ≥ 5 cm, pose substantial clinical challenges. This structured narrative review distinguishes giant-specific findings from contextual evidence in advanced or high-risk disease. Methods: The synthesis uses a retained bibliography assembled from searches described in earlier drafts as covering PubMed/MEDLINE and PubMed Central from January 2015 to March 2026, supplemented by citation and guideline searching and a focused update reported through 4 September 2026. A record-level search and screening log is unavailable; historical selection counts cannot be independently reconstructed. The review protocol was not registered, and exhaustive coverage or full PRISMA compliance is not claimed. Sources were classified by design and directness, with descriptive consideration of methodological limitations. Results: The retained set contains 51 sources: nine containing direct giant-specific clinical evidence and 42 providing contextual evidence. Direct evidence consists principally of case reports, retrospective or comparative studies and a giant-cSCC literature synthesis. It links giant BCC with prolonged lesion duration, ulceration, deeper invasion and reconstructive burden. Giant-cSCC outcomes vary substantially between reported series. Evidence for Hedgehog-pathway inhibition, PD-1 blockade and most molecular mechanisms derives mainly from conventional or advanced disease. Conclusions: Management requires multidisciplinary assessment integrating size, pathological risk, resectability and patient factors. Giant-specific molecular and therapeutic evidence remains limited, and contextual treatment effects should not be interpreted as effects established specifically in tumours ≥ 5 cm.
SN  - 2072-6694
ER  -